Why the study?
Pulmonary embolism presentation is often non-specific and individual molecular and ECG biomarkers have limited diagnostic accuracy.
Does AI-driven integration of ECG and molecular biomarkers improve diagnostic accuracy and risk assessment in patients with pulmonary embolism?
Does AI-driven integration of ECG and molecular biomarkers improve diagnostic accuracy and risk assessment in patients with pulmonary embolism?
AI-driven integration of ECG and molecular biomarkers represents a promising approach to overcome the limited diagnostic accuracy of individual markers in pulmonary embolism.
Answers are grounded in this paper and cite their sources.
Should not yet alter PE practice; leaves open whether prospective validation will confirm AI-ECG-biomarker utility.
Pulmonary embolism (PE) is a serious cardiovascular condition and the third leading cause of cardiovascular mortality worldwide. However, its clinical presentation is often non-specific, making timely detection challenging. Biomarkers are commonly used to support early diagnosis and risk stratification. Molecular biomarkers provide information related to coagulation, inflammation, and cardiac injury. Electrocardiography (ECG) reflects cardiac functional changes caused by right ventricular (RV) stress and dilation secondary to increased pulmonary vascular resistance. Individually, these biomarkers have limited diagnostic accuracy. A promising approach to improving PE management involves integrating multimodal clinical data using Artificial Intelligence (AI). AI-based models can detect subtle patterns in ECG signals and molecular biomarker profiles that may be missed by conventional analysis. Combining these data sources may enhance diagnostic accuracy, refine risk assessment, and support personalized treatment. Despite ongoing challenges, including data quality, interpretability, and ethical considerations, AI-driven integration of ECG and molecular biomarkers represents a significant step forward in PE diagnosis and management. Further validation in large, prospective clinical studies is required.
No takes yet. Share an insight, caveat, or question.
Uzelac et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: